TherapeuticsMD Inc (TXMD) Upgraded to “Hold” by Zacks Investment Research
TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Separately, Noble Financial restated a “buy” rating and set a $17.50 price target on shares of TherapeuticsMD in a research note on Monday, July 11th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/therapeuticsmd-inc-txmd-upgraded-to-hold-by-zacks-investment-research.html
TherapeuticsMD (NASDAQ:TXMD) opened at 6.71 on Wednesday. The company’s market cap is $1.32 billion. TherapeuticsMD has a 52-week low of $5.18 and a 52-week high of $11.26. The company’s 50-day moving average is $6.73 and its 200 day moving average is $7.68.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The business earned $4.40 million during the quarter, compared to analyst estimates of $5.63 million. The firm’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.16) EPS. Equities analysts forecast that TherapeuticsMD will post ($0.43) earnings per share for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.